NEW
YORK, Nov. 18, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
today announced that company management will present at the
Canaccord Genuity MedTech, Diagnostics and Digital Health &
Services Forum in New York on
Thursday, November 21, 2024 at
1:30 p.m. ET.
Live and replay webcasts may be accessed on the investor
relations section of the Company's website at ir.luciddx.com. The
webcast will be archived and available for replay for at least 30
days after the event.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company and
subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the
millions of patients with gastroesophageal reflux disease (GERD),
also known as chronic heartburn, who are at risk of developing
esophageal precancer and cancer. Lucid's EsoGuard®
Esophageal DNA Test, performed on samples collected in a brief,
noninvasive office procedure with its EsoCheck®
Esophageal Cell Collection Device, represent the first and only
commercially available tools designed with the goal of preventing
cancer and cancer deaths through widespread, early detection of
esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com
and for more information about its parent company PAVmed, please
visit www.pavmed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-302308185.html
SOURCE Lucid Diagnostics